Crohn's disease is usually caught after the bowel is already scarred, and no blood test reliably tells you who will develop it years ahead of symptoms. A clinical proteomics study in Nature Communications took aim at that gap, measuring 2,736 plasma proteins in 39,634 UK Biobank adults and tracking them for a median of 13.6 years. The question was blunt: can a protein pattern from one blood draw flag future Crohn's disease long before a gastroenterologist is ever involved? Ke

```html Blood tests for Alzheimer's disease still lean on amyloid and tau, yet lipid changes surface in neurons long before plaques dominate a scan. A team at China Pharmaceutical University went after that gap. They profiled 156 people spanning normal cognition, amnestic mild cognitive impairment, and Alzheimer's, then built lipidomics biomarkers from two blood compartments at once: plasma and the red blood cell membrane. The payoff is a six-lipid panel that told patients fr

The failing heart runs low on fuel well before symptoms force a diagnosis, yet routine cardiology almost never measures that fuel directly. A serum metabolomics study of 210 patients set out to map the shortfall across the ACC/AHA stages of heart failure. Xiao Zhang and colleagues paired untargeted screening with a targeted energy-metabolite panel, then asked which molecules track the slide from at-risk Stage A to symptomatic Stage C. Their answer points straight at the cell'

Muscle wasting and bone loss usually get worked up in different clinics, by different specialists, with different biomarker panels. That split ignores how tightly the two tissues are wired together. A new multi-omics study in Aging Cell used UK Biobank data to test whether sarcopenia and osteoporosis actually feed each other, then went looking for the plasma proteins and metabolites that carry the signal from muscle to bone. Key Takeaways Grip strength and walking pace each p

Clinicians managing an acute COPD exacerbation in a patient living with HIV face a hard question at discharge: who is about to relapse within three months? The usual severity scores were not built for this dual-inflammation phenotype. A recent multi-omics study paired serum proteomics with untargeted metabolomics across HIV-AECOPD, AECOPD-alone, and healthy control groups, then tested the strongest signals in a separate cohort. The winning marker was cheap and already on ever